The Company's common stock will continue to trade under the symbol "CYTX" following the transfer of its listing to The NASDAQ Capital Market tier. The continued listing of the Company's common stock on The NASDAQ Capital Market …
A year ago, they were trading at 95 cents. This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CYTX …
ticker=CYTX Repros Therapeutics Inc. https://rdinvesting.com/news/?ticker=RPRX Cytori Therapeutics Inc.'s stock jumped 29.55% Friday, to close the day at $0.63. The stock recorded a trading volume of 19,354,894 shares, which was above …
Cytori Therapeutics, Inc. (NASDAQ: CYTX) entered into a definitive securities purchase ... with each unit consisting of one share of its Series A 3.6% convertible preferred stock, which shall be convertible into the Company's common stock …
SAN DIEGO--(BUSINESS WIRE)--Cytori Therapeutics, Inc. (NASDAQ: CYTX) today announced that it has received formal confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) that Cytori’s request for an oral hearing with the Nasdaq …
Cytori Therapeutics Inc. (NASDAQ: CYTX), Endo Health Solutions Inc. (NASDAQ ... This is now about 5-times normal trading volume and the stock hit a yearly high of $14.07 earlier in the day. This move took the market cap up to over …
Each of these rates a “D” (“sell”) or “F” overall (“strong sell”). Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures.
The company now expects full year contract revenue to range between $275 million and $283 million, up from its prior outlook of $ ... events. CYTX closed Tuesday's trading at $2.10, down 0.47%. In after-hours, the stock was down …
As such, SmarTrend will continue to monitor shares of CYTX to see if this bullish momentum will continue. SmarTrend …
Shares of Rambus (Nasdaq: RMBS) are up more than 6% with about 20 minutes left in this morning's pre-market session. Traders are responding to news that the company and NVIDIA (Nasdaq: NVDA) signed a patent license agreement …